Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Bethge WA, Martus P, Schmitt M, Holtick U, Borchmann P, Subklewe M, Rejeski K, Tresckow B, Ayuk FA, Kroeger N, Wagner-Drouet EM, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, Von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Wolff D, Schroers R, Thomas S, Beelen DW, Lengerke C, Dreger P (2021)


Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Pages Range: 3822-+

Conference Proceedings Title: BLOOD

DOI: 10.1182/blood-2021-146120

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Bethge, W.A., Martus, P., Schmitt, M., Holtick, U., Borchmann, P., Subklewe, M.,... Dreger, P. (2021). Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis. In BLOOD (pp. 3822-+). WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Bethge, Wolfgang A., et al. "Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis." Proceedings of the BLOOD WASHINGTON: AMER SOC HEMATOLOGY, 2021. 3822-+.

BibTeX: Download